Premium
ORIGINAL ARTICLE: A Retrospective Analysis of Fondaparinux Versus Enoxaparin Treatment in Women with Infertility or Pregnancy Loss
Author(s) -
Winger Edward E.,
Reed Jane L.
Publication year - 2009
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.1600-0897.2009.00733.x
Subject(s) - fondaparinux , medicine , miscarriage , obstetrics , pregnancy , infertility , low molecular weight heparin , retrospective cohort study , gynecology , heparin , surgery , thrombosis , venous thromboembolism , biology , genetics
Problem We compared the pregnancy success rates and safety parameters of fondaparinux versus enoxaparin, combined with immunotherapy, in patients with a history of miscarriage and/or infertility and coagulant defects. Method of study A total of 127 pregnancies in 110 patients with a history of miscarriage and/or infertility were retrospectively evaluated. Of these, 29 pregnancies used fondaparinux 2.5 mg daily and 98 pregnancies used enoxaparin 30 mg twice daily. Results The pregnancy success rate was 59% (17/29; 95% CI, 41–75%) for patients receiving fondaparinux and 58% (57/98; 95% CI, 48–68%) for patients receiving enoxaparin. No difference was detected in birth weight (2.7 ± 0.8 and 2.9 ± 0.6 kg, respectively) or gestational age at delivery (37.3 ± 2.2 and 37.7 ± 2.1 weeks, respectively). No birth defects, severe bleeding‐related complications, or serious allergic reactions were observed. Conclusion In patients with a history of miscarriage, infertility, and coagulant defects receiving immunotherapy, fondaparinux resulted in successful pregnancy outcomes comparable with enoxaparin therapy. Although no difference in outcome was observed in our analysis, a much larger study is required to achieve statistical power.